
    
      We hypothesize that riluzole will lead to significant reduction in depressive symptoms as
      measured by the Hamilton Depression Rating Scale (HAM-D). Additionally, improvement in
      depressive symptoms will be associated with reduced glutamate levels in the anterior
      cingulate cortex, but not parieto-occipital cortex, both at day two and day 42.
    
  